AFMDQ (Affimed NV) Debt-to-Asset : 0.32 (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Debt-to-Asset?

Affimed NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $7.66 Mil. Affimed NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $6.64 Mil. Affimed NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $44.35 Mil. Affimed NV's debt to asset for the quarter that ended in Sep. 2024 was 0.32.

Affimed NV Debt-to-Asset Historical Data

The historical data trend for Affimed NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Debt-to-Asset Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.01

0.08

0.09

0.20

Affimed NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.18	0.20	0.23	0.27	0.32

Competitive Comparison of Affimed NV's Debt-to-Asset

For the Biotechnology subindustry, Affimed NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Affimed NV's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Affimed NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Affimed NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(6.949	+	14.154)	/	105.951
	=	0.20

Affimed NV's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(7.661	+	6.644)	/	44.35
	=	0.32

Affimed NV (OTCPK:AFMDQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Affimed NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Affimed NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (OTCPK:AFMDQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

0HL9:UK

Address

Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.